These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31466437)

  • 41. Dual Stimuli-Responsive Controlled Release Nanocarrier for Multidrug Resistance Cancer Therapy.
    Jiao X; Wang Z; Wang F; Wen Y
    Chemphyschem; 2019 Dec; 20(24):3271-3275. PubMed ID: 31654459
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pluronic-based functional polymeric mixed micelles for co-delivery of doxorubicin and paclitaxel to multidrug resistant tumor.
    Chen Y; Zhang W; Huang Y; Gao F; Sha X; Fang X
    Int J Pharm; 2015 Jul; 488(1-2):44-58. PubMed ID: 25899286
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dual-responsive mPEG-PLGA-PGlu hybrid-core nanoparticles with a high drug loading to reverse the multidrug resistance of breast cancer: an in vitro and in vivo evaluation.
    Xu H; Yang D; Cai C; Gou J; Zhang Y; Wang L; Zhong H; Tang X
    Acta Biomater; 2015 Apr; 16():156-68. PubMed ID: 25662165
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reduction/photo dual-responsive polymeric prodrug nanoparticles for programmed siRNA and doxorubicin delivery.
    Wu M; Li J; Lin X; Wei Z; Zhang D; Zhao B; Liu X; Liu J
    Biomater Sci; 2018 May; 6(6):1457-1468. PubMed ID: 29770812
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsions in reversing multidrug resistance in breast cancer in vitro and in vivo.
    Cao X; Luo J; Gong T; Zhang ZR; Sun X; Fu Y
    Mol Pharm; 2015 Jan; 12(1):274-86. PubMed ID: 25469833
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
    Zhang ZL; Jiang QC; Wang SR
    Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers.
    Wang C; Sun X; Wang K; Wang Y; Yang F; Wang H
    Drug Deliv; 2016 Oct; 23(8):2697-2702. PubMed ID: 26203692
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
    Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
    J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
    Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
    Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Doxorubicin and adjudin co-loaded pH-sensitive nanoparticles for the treatment of drug-resistant cancer.
    Wang Q; Zou C; Wang L; Gao X; Wu J; Tan S; Wu G
    Acta Biomater; 2019 Aug; 94():469-481. PubMed ID: 31141733
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
    Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
    Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
    Wong HL; Bendayan R; Rauth AM; Wu XY
    J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Temperature Self-Limited Intelligent Thermo-chemotherapeutic Lipid Nanosystem for P-gp Reversal Time Window Matched Pulse Treatment of MDR Tumor.
    Zhou J; Shen W; Feng W; Zhang X; Wu T; Zhou J; Su Z; Yin T
    Nano Lett; 2024 Aug; 24(34):10631-10641. PubMed ID: 39150779
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hybrid Mesoporous-Microporous Nanocarriers for Overcoming Multidrug Resistance by Sequential Drug Delivery.
    Wang L; Guan H; Wang Z; Xing Y; Zhang J; Cai K
    Mol Pharm; 2018 Jul; 15(7):2503-2512. PubMed ID: 29768014
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug.
    Ling L; Ismail M; Du Y; Yao C; Li X
    Int J Pharm; 2019 Apr; 560():246-260. PubMed ID: 30769133
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Indocyanine green/doxorubicin-encapsulated functionalized nanoparticles for effective combination therapy against human MDR breast cancer.
    Chen HH; Lu IL; Liu TI; Tsai YC; Chiang WH; Lin SC; Chiu HC
    Colloids Surf B Biointerfaces; 2019 May; 177():294-305. PubMed ID: 30771581
    [TBL] [Abstract][Full Text] [Related]  

  • 58. pH and near-infrared light dual-stimuli responsive drug delivery using DNA-conjugated gold nanorods for effective treatment of multidrug resistant cancer cells.
    Zhang W; Wang F; Wang Y; Wang J; Yu Y; Guo S; Chen R; Zhou D
    J Control Release; 2016 Jun; 232():9-19. PubMed ID: 27072026
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.
    Shen J; He Q; Gao Y; Shi J; Li Y
    Nanoscale; 2011 Oct; 3(10):4314-22. PubMed ID: 21892492
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Doxorubicin-loaded NaYF4:Yb/Tm-TiO2 inorganic photosensitizers for NIR-triggered photodynamic therapy and enhanced chemotherapy in drug-resistant breast cancers.
    Zeng L; Pan Y; Tian Y; Wang X; Ren W; Wang S; Lu G; Wu A
    Biomaterials; 2015 Jul; 57():93-106. PubMed ID: 25913254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.